23 Results

People

  1. Abdel-Wahab
    Abdel-Wahab
  2. Rampal
    Rampal
  3. Diamond
    Diamond
  4. Durham
    Durham
  5. Lacouture
    Lacouture
  6. Hyman
    Hyman
  7. Tallman
    Tallman
  8. Chung
    Chung
  9. Rosen
    Rosen
  10. Dogan
    Dogan

Groups

  1. Adult Leukemia (23)
  2. Center for Hematologic Malignancies (23)
  3. Department of Medicine (23)
  4. Executive Committee, Center for Hematologic Malignancies (23)
  5. GSK Faculty (23)
  6. Hematologic Malignancies, Division of (23)
  7. Human Oncology and Pathogenesis Program (23)
  8. Survivorship Research (23)
  9. Tow Center for Developmental Oncology (TCDO) (23)
  10. Division of Subspecialty Medicine (15)
  1. "Omar Abdel-Wahab"
  2. "Adult Leukemia"
  3. "Survivorship Research"
Formats
  1. Meeting Abstract (13)
  2. Journal Article (10)
Groups
  1. Adult Leukemia (23)
  2. Center for Hematologic Malignancies (23)
  3. Department of Medicine (23)
  4. Executive Committee, Center for Hematologic Malignancies (23)
  5. GSK Faculty (23)
  6. Hematologic Malignancies, Division of (23)

More Groups

People
  1. Omar Abdel-Wahab (23)
  2. Mario Lacouture (14)
  3. Raajit Rampal (12)
  4. Eli Diamond (11)
  5. Ahmet Dogan (9)
  6. Benjamin Durham (9)

More People

Years
  1. 2023 (6)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (2)
  6. 2018 (1)

More Years

Publications
  1. Blood (7)
  2. Journal of Clinical Oncology (3)
  3. British Journal of Haematology (2)
  4. Pediatric Blood and Cancer (2)
  5. American Journal of Hematology (1)
  6. Blood Advances (1)

More Publications

Publishers
  1. American Society of Hematology (8)
  2. American Society of Clinical Oncology (3)
  3. John Wiley & Sons (2)
  4. Wiley Periodicals, Inc (2)
  5. American Association for Cancer Research (1)
  6. American Society for Clinical Investigation (1)

More Publishers

Results (23)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 2 trial of single-agent cobimetinib for adults with histiocytic neoplasms
    Meeting Abstract

    Diamond, E. L.; Durham, B.; Dogan, A.; Yabe, M.; Petrova-Drus, K.; Rampal, R. K.; Ulaner, G.; Lacouture, M.; Rotemberg, V.; Covey, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms
    Journal Article

    Reiner, A. S.; Durham, B. H.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V.; Abdel-Wahab, O.; Panageas, K. S.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings
    Meeting Abstract

    Walsh, M. F.; Fiala, E.; Birsoy, O.; Haque, T.; Stein, E. M.; Shukla, N.; Sulis, M. L.; Goldberg, A. D.; Rana, S.; Khurram, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including novel treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Rosenblum, M.; Yabe, M.; Petrova-Drus, K.; Francis, J. H.; Rampal, R. K.; Lacouture, M. E.; Rotemberg, V. M.; Hatzoglou, V.; Young, R.; more...
    Pediatric Blood and Cancer (2023)

    Fulltext@MSK | Save
  • Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
    Journal Article

    Stahl, M.; Derkach, A.; Farnoud, N.; Bewersdorf, J. P.; Robinson, T.; Famulare, C.; Cho, C.; Devlin, S.; Menghrajani, K.; Patel, M. A.; more...
    American Journal of Hematology (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib
    Meeting Abstract

    Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia
    Meeting Abstract

    Stahl, M.; Derkach, A.; Famulare, C.; Cho, C.; Devlin, S.; Farnoud, N.; Menghrajani, K.; Patel, M. A.; Cai, S. F.; Geyer, M. B.; more...
    Blood (2020)

    Fulltext@MSK | Save